Fitxa persona

Pau Arroyo Mañez has been a Tenured Associate Professor in the Department of Organic Chemistry at the University of Valencia since 2023 and has served as Head of the Department since March 2024. He holds a PhD in Organic and Pharmaceutical Chemistry and completed his doctoral thesis in computational chemistry under the supervision of Prof. Luis R. Domingo and Prof. María Teresa Picher, focusing on the study of reaction mechanisms in organic chemistry, with particular emphasis on cycloaddition reactions.

He carried out his postdoctoral research at the University of Buenos Aires (2008–2013) under a CONICET postdoctoral fellowship, working on the computational modeling of proteins of biomedical interest. In 2013, he joined the CONICET Scientific Researcher Career, and in 2015 he was promoted to Associate Researcher, a position he held until 2019. His research during this period focused on the modeling of organic chemical processes and the rational design of drugs, while also contributing to the training of early-career researchers.

In 2019, he joined the University of Valencia as an Assistant Professor and became a member of the MODeLiC research group, where he has conducted research on molecular sensors for the detection of drugs used in drug-facilitated crimes and on nanosystems for the controlled release of drugs in hypoxic environments. In 2023, he was appointed Tenured Associate Professor.

He has published 38 scientific articles (including 3 review articles), 2 book chapters, and more than 50 contributions to national and international conferences. He has served as principal investigator on 3 competitive research projects and has participated in approximately 20 additional projects. He holds three recognized teaching quinquenniums and three research sexenniums awarded by ANECA. He is a founding partner of the spin-off company OpticalSens, dedicated to the development of chemical sensors with social impact through its Celentis product line.

His research interests include chromofluorogenic sensors, theranostic nanosystems, and the rational design of enzyme inhibitors.